---
schema_version: "secwatch.filing_event.v1"
accession: "0001295947-23-000006"
form_type: "8-K"
ticker: "PBH"
cik: "0001295947"
company_name: "Prestige Consumer Healthcare Inc."
filed_at: "2023-02-02T23:59:59+00:00"
generated_at: "2026-06-20T01:56:20.139926+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Prestige Q3 revenue $275.5M (+0.4%), EPS $1.04 (+5.1%); guides FY23 EPS ~$4.18

## Summary
- Q3 revenue $275.5M (+0.4% YoY; +1.8% ex-currency); diluted EPS $1.04 (+5.1% vs $0.99).
- International OTC revenue $38.6M (+15% YoY); North American OTC $236.9M (-1.7%).
- Leverage ratio reduced to 3.5x, lowest in over 10 years; net debt ~$1.4B.
- FY2023 guidance: revenue $1,120-1,122M, diluted EPS ~$4.18, free cash flow ~$220M.
- Nine-month revenue $841.9M (+2.7% YoY); net income $158.2M vs $153.3M.

## SEC filing metadata
- accession: 0001295947-23-000006
- form_type: 8-K
- ticker: PBH
- cik: 0001295947
- company_name: Prestige Consumer Healthcare Inc.
- filed_at: 2023-02-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1295947/000129594723000006/0001295947-23-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1295947/000129594723000006/pbh-20230202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001295947-23-000006
- JSON: https://secwatch.observer/filing/0001295947-23-000006.json
- Plain text: https://secwatch.observer/filing/0001295947-23-000006.txt

## Key facts
- Earnings Releases
  Prestige Consumer Healthcare Inc. reported third fiscal quarter ended December 31, 2022 results: revenue $275.5 million, net income $52.0 million, EPS $1.04.
  - Period: third fiscal quarter ended December 31, 2022
  - Revenue: $275.5 million
  - Net income: $52.0 million
  - EPS: $1.04
  - Result: reported results
  source text: Reported revenues in the third quarter of fiscal 2023 of $275.5 million increased 0.4% from $274.5 million in the third quarter of fiscal 2022. Revenues increased 1.8% excluding the impact of foreign currency. The revenue growth for the quarter was led by strong performance in our International OTC segment and strong Cough & Cold category sales versus the prior year comparable period. Reported net income for the third quarter of fiscal 2023 totaled $52.0 million, compared to the prior year third quarter’s net income of $50.2 million. Diluted earnings per share of $1.04 for the third quarter of fiscal 2023 compared to diluted earnings per share of $0.99 in the prior year comparable period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1295947/000129594723000006/0001295947-23-000006-index.htm
- Earnings Releases
  Prestige Consumer Healthcare Inc. reported fiscal year 2023 results: revenue $1,120 and $1,122.
  - Period: fiscal year 2023
  - Revenue: $1,120 and $1,122
  - Result: guidance update
  source text: With one quarter to go in fiscal year 2023 we anticipate sales between $1,120 and $1,122 equating to over 3% growth on top of our record fiscal 2022 results.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1295947/000129594723000006/0001295947-23-000006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.